UNSPSC 51386201: Acexamic acid

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IC4BO7D3R. European Medicines Agency schedules Acexamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05234MIG. Acexamic acid generally arises in the molecular formula C8H15NO3. The term ACEXAMIC ACID is an International Nomenclature of Cosmetic Ingredients designation. Most nations schedule acexamic acid under HS 29241900 and SITC 51471.

As of Q4 2014, ACEXAMIC ACID remains the US FDA Preferred Term for this commodity. Acexamic acid bears US NLM identifiers UMLS ID C0049477 and NCI Concept Code C80535. SMILES: OC(=O)CCCCCNC(=O)C.

UNSPSC 51386201 Acexamic acid is a Commodity code that, based on recent state and local procurement activity, does not align with the opportunities currently being solicited under this designation. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are acexamic acid or closely related chemical compounds. The mismatch suggests either miscoding in the posting systems or that acexamic acid procurement through state and local bodies is minimal or nonexistent in the recent record.

The issuing bodies represent a mix of county health departments, state health agencies, and cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 for naloxone and drug deactivation systems with a due date of July 26, 2023 (note: date discrepancy in source); the Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration posted an RFP on January 20, 2026 with a due date of March 26, 2026 for generic pharmaceuticals and OTC products across multiple state and local jurisdictions, including Oregon. The geographic footprint spans Florida, Texas, Minnesota, and Oregon. No recent activity specifically targeting acexamic acid has been identified in state and local procurement.